Download PDF
Thromb Haemost 2009; 102(05): 914-915
DOI: 10.1160/TH09-08-0563
Pro/Contra Article
Schattauer GmbH

Contra: “Anti-platelet therapy is an alternative to oral anticoagulation for atrial fibrillation”

Stavros Apostolakis
1   Haemostasis Thrombosis and Vascular Biology Unit, University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, UK
,
Eduard Shantsila
1   Haemostasis Thrombosis and Vascular Biology Unit, University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, UK
,
Gregory Y. H. Lip
1   Haemostasis Thrombosis and Vascular Biology Unit, University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, UK
,
Deirdre A. Lane
1   Haemostasis Thrombosis and Vascular Biology Unit, University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, UK
› Author Affiliations
Further Information

Publication History

Received: 14 August 2009

Accepted after minor revision: 29 September 2009

Publication Date:
27 November 2017 (online)

    Permissions and Reprints

 

 

  • References

  • 1 Hughes M, Lip GY. Guideline Development Group National Clinical Guideline for Management of Atrial Fibrillation in Primary and Secondary Care National Institute for Health and Clinical Excellence Stroke and thromboembolism in atrial fibrillation: a systematic review of stroke risk factors, risk stratification schema and cost effectiveness data. Thromb Haemost 2008; 99: 295-304.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 2 Poli D, Antonucci E, Grifoni E. et al. Gender differences in stroke risk of atrial fibrillation patients on oral anticoagulant treatment. Thromb Haemost 2009; 101: 938-942.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 3 Fuster V, Rydén LE, Cannom DS. et al. American College of Cardiology; American Heart Association Task Force; European Society of Cardiology Committee for Practice Guidelines; European Heart Rhythm Association;Heart Rhythm Society ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 guidelines for the management of patients with atrial fibrillation) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Europace 2006; 08: 651-745.
    CrossrefPubMedGoogle Scholar
  • 4 Palareti G, Cosmi B. Bleeding with anticoagulation therapy - who is at risk, and how best to identify such patients. Thromb Haemost 2009; 102: 268-278.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 5 McBane RD, Hodge DO, Wysokinski WE. Clinical and echocardiographic measures governing throm-boembolism destination in atrial fibrillation. Thromb Haemost 2008; 99: 951-955.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 6 Singer DE, Chang Y, Fang MC. et al. The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med 2009; 151: 297-305.
    CrossrefPubMedGoogle Scholar
  • 7 Lip GY. Paroxysmal atrial fibrillation, stroke risk and thromboprophylaxis. Thromb Haemost 2008; 100: 11-13.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 8 The ACTIVE Writing Group on behalf of the ACTIVE Investigators: Clopidogrel plus aspirin versus oral anticoagulation for atrial fi brillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet. 2006 367. 1903-1912.
    PubMedGoogle Scholar
  • 9 The ACTIVE Investigators: Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med. 2009 360. 2066-2067.
    PubMedGoogle Scholar
  • 10 Man-Son-Hing M, O’Connor AM, Drake E. et al. The effect of qualitative vs. quantitative presentation of probability estimates on patient decision-making: a randomized trial. Health Expect 2002; 05: 246-255.
    PubMedGoogle Scholar
  • 11 Nieuwlaat R, Capucci A, Camm AJ. et al. Euro Heart Survey Investigators: Atrial fibrillation management: A prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J 2005; 26: 2422-2434.
    CrossrefPubMedGoogle Scholar
  • 12 Jeffrey S. ACTIVE-A: Clopidogrel and aspirin reduce CV events in atrial fibrillation. theheart.org. [Clinical Conditions > Arrhythmia/EP > Arrhythmia/ EP]; Mar 31, 2009. Accessed at http://www.theheart. org/article/955787 do on Aug 12. 2009
    PubMedGoogle Scholar
  • 13 Mant JW. Pro: ‘Warfarin should be the drug of choice for thromboprophylaxis in elderly patients with atrial fibrillation’. Why warfarin should really be the drug of choice for stroke prevention in elderly patients with atrial fibrillation. Thromb Haemost 2008; 100: 14-15.
    PubMedGoogle Scholar
  • 14 Hylek EM. Contra: ‘Warfarin should be the drug of choice for thromboprophylaxis in elderly patients with atrial fibrillation’. Caveats regarding use of oral anticoagulant therapy among elderly patients with atrial fibrillation. Thromb Haemost 2008; 100: 16-17.
    PubMedGoogle Scholar
  • 15 Connolly SJ, Pogue J, Eikelboom J, Flaker G, Commerford P, Franzosi MG, Healey JS, Yusuf S. ACTIVE W Investigators: Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centres and countries as measured by time in therapeutic range. Circulation 2008; 118: 2029-2037.
    CrossrefPubMedGoogle Scholar
  • 16 Tay KH, Lip GY, Lane DA. Atrial fibrillation and stroke risk prevention in real-life clinical practice. Thromb Haemost 2009; 101: 415-416.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 17 Connolly SJ, Ezekowitz MD, Yusuf S. et al. The RELY Steering Committee and Investigators. Dabigatran versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med. 2009 epub ahead of print..
    PubMedGoogle Scholar
  • 18 Lip GYH, Nieuwlaat R, Pisters R. et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor based approach: The Euro Heart Survey on Atrial Fibrillation. Chest. 2009 epub ahead of print..
    PubMedGoogle Scholar